These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 32585180)
41. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. Wambier CG; Goren A J Am Acad Dermatol; 2020 Jul; 83(1):308-309. PubMed ID: 32283245 [TBL] [Abstract][Full Text] [Related]
42. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. Ulrich H; Pillat MM Stem Cell Rev Rep; 2020 Jun; 16(3):434-440. PubMed ID: 32307653 [TBL] [Abstract][Full Text] [Related]
43. COVID-19-activated SREBP2 disturbs cholesterol biosynthesis and leads to cytokine storm. Lee W; Ahn JH; Park HH; Kim HN; Kim H; Yoo Y; Shin H; Hong KS; Jang JG; Park CG; Choi EY; Bae JS; Seo YK Signal Transduct Target Ther; 2020 Sep; 5(1):186. PubMed ID: 32883951 [TBL] [Abstract][Full Text] [Related]
44. Leukoerythroblastosis and plasmacytoid lymphocytes in a child with SARS-CoV-2-associated multisystem inflammatory syndrome. Lee WS; Margolskee E Blood; 2020 Aug; 136(7):914. PubMed ID: 32790856 [No Abstract] [Full Text] [Related]
45. SARS-CoV-2: An immunogenetics call to arms. Clark B; Poulton K Int J Immunogenet; 2020 Aug; 47(4):319-323. PubMed ID: 32654378 [TBL] [Abstract][Full Text] [Related]
46. COVID-19 pathophysiology: A review. Yuki K; Fujiogi M; Koutsogiannaki S Clin Immunol; 2020 Jun; 215():108427. PubMed ID: 32325252 [TBL] [Abstract][Full Text] [Related]
47. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment. Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295 [TBL] [Abstract][Full Text] [Related]
48. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm. Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027 [No Abstract] [Full Text] [Related]
49. SARS-CoV-2 immunogenicity at the crossroads. Karamloo F; König R Allergy; 2020 Jul; 75(7):1822-1824. PubMed ID: 32401346 [No Abstract] [Full Text] [Related]
51. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids. Miao Y; Fan L; Li JY Front Immunol; 2020; 11():1445. PubMed ID: 32612616 [No Abstract] [Full Text] [Related]
52. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia. Rivellese F; Prediletto E Autoimmun Rev; 2020 Jun; 19(6):102536. PubMed ID: 32251718 [No Abstract] [Full Text] [Related]
56. Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes. Debnath M; Banerjee M; Berk M FASEB J; 2020 Jul; 34(7):8787-8795. PubMed ID: 32525600 [TBL] [Abstract][Full Text] [Related]
57. Cancer therapy and treatments during COVID-19 era. Akula SM; Abrams SL; Steelman LS; Candido S; Libra M; Lerpiriyapong K; Cocco L; Ramazzotti G; Ratti S; Follo MY; Martelli AM; Blalock WL; Piazzi M; Montalto G; Cervello M; Notarbartolo M; Basecke J; McCubrey JA Adv Biol Regul; 2020 Aug; 77():100739. PubMed ID: 32773105 [TBL] [Abstract][Full Text] [Related]
58. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19. Moutsopoulos HM Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616 [No Abstract] [Full Text] [Related]
59. COVID-19, severe asthma, and biologics. García-Moguel I; Díaz Campos R; Alonso Charterina S; Fernández Rodríguez C; Fernández Crespo J Ann Allergy Asthma Immunol; 2020 Sep; 125(3):357-359.e1. PubMed ID: 32553608 [No Abstract] [Full Text] [Related]
60. The many faces of the anti-COVID immune response. Vardhana SA; Wolchok JD J Exp Med; 2020 Jun; 217(6):. PubMed ID: 32353870 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]